

No: 33../2025/CV-VMD

About: Explaining the fluctuation of over 10% in  
the business performance on the separate financial  
statements and consolidated financial statements of  
the first quarter of 2025 compared to the first  
quarter of 2024

Ha Noi, 29.. April 2025

**TO:**           **The State Securities Commission**  
                    **Ho Chi Minh City Stock Exchange**

Pursuant to the guidance in Circular No. 96/2020/TT-BTC dated November 16, 2020 of the Ministry of Finance on guidance on information disclosure on the stock market, Vimedimex Pharmaceutical Joint Stock Company (Vimedimex Company), stock code: VMD, explains the profit fluctuations in the first quarter of 2025 compared to the first quarter of 2024 on the Separate Financial Statements and Consolidated Financial Statements as follows:

Content	1st quarter of 2025	1st quarter of 2024	Difference	% Increase/Decrease
Profit after corporate income tax – Separate Financial Statements	3,264,055,111	1,814,754,228	1,449,300,883	79.86%
Profit after corporate income tax – Consolidated Financial Statements	3,872,206,906	2,778,780,942	1,093,425,964	39.35%

**In the Separate Financial Statements:**

Profit after corporate income tax in the first quarter of 2025 in the separate financial report increased by **VND 1,449,300,883**, equivalent to an increase of **79.86%** compared to the same period in 2024, mainly due to:

- Revenue from sales and service provision in the first quarter of 2025 increased by **VND 404,583,808**, equivalent to **1.9%** over the same period in 2024.

- Financial revenue in the first quarter of 2025 increased by **VND 704,926,755**, equivalent to **74.05%** over the same period in 2024.

- However, the company reduced costs in the first quarter of 2025 compared to the same period in 2024: financial expenses decreased by **VND 635,302,816**, selling expenses increased by **VND 1,051,579,143**, equivalent to **45.23%**, but management expenses decreased by **VND 1,023,025,500**, equivalent to **29.61%**



### **In the Consolidated Financial Statements:**

Profit after corporate income tax in the first quarter of 2025 in the Consolidated Financial Statements increased by **VND 1,093,425,964**, equivalent to an increase of **39.35%** compared to the same period in 2024, mainly due to:

- Revenue from sales and service provision in the first quarter of 2025 decreased by **VND 112,136,948,174**, equivalent to **31.56%** compared to the same period in 2024.

- Revenue from financial activities in the first quarter of 2025 increased by **VND 630,640,619**, equivalent to **42.06%** compared to the same period in 2024.

- Business management expenses increased by **VND 1,192,009,986**, equivalent to **20.38%**, however, Sales expenses decreased by **VND 775,364,351**, equivalent to **4.06%**, financial expenses The main price decreased by **1,325,535,510 VND**, equivalent to **61.48%**.

Vimedimex Medi - Pharma Joint Stock Company would like to report and explain the fluctuation of over 10% in Business Performance Results on the Separate Financial Statements and Consolidated Financial Statements for the first Quarter of 2025 compared to the same period in 2024. Vimedimex Medi - Pharma Joint Stock Company commits that the above information is true./.

Best regards!

#### **Recipients:**

- As above;
- Board of Directors (for report);
- Archive: Clerical./.

**VIMEDIMEX MEDI - PHARMA JOINT STOCK  
COMPANY**



*[Handwritten signature]*  
**TỔNG GIÁM ĐỐC**  
*Trần Mỹ Linh*

